A new Phase I trial launches to test personalized neoantigen vaccines with pembrolizumab in renal cell carcinoma, addressing resistance to standard immunotherapy.trial
Meanwhile, Merck highlights its partnership with Moderna on individualized therapies, and a new computational method, TCR-FramePose, offers improved geometric modeling for TCR-pMHC docking.The AtlanticbioRxiv
Peking University First Hospital is launching a Phase I investigator-initiated trial to evaluate a personalized neoantigen polyepitope peptide vaccine combined with pembrolizumab in advanced renal cell carcinoma. The study aims to enroll 5-8 patients across safety and expansion cohorts to address the high rate of primary or acquired resistance to pembrolizumab monotherapy.
Researchers have introduced TCR-FramePose, a local-frame representation method that decomposes TCR-pMHC docking geometry into reach, offset, and orientation coordinates. Applied to 378 crystal structures, the tool captures CDR3 loop geometry and affinity-associated information beyond conventional descriptors, potentially improving the computational prediction of T cell receptor recognition.
Relevant work from earlier we're still surfacing — not today's news.